Note: For a full background on OMER, please see our Top Idea article from July 15, 2019.
On July 15, 2019, we published a Top Idea article on Omeros Corporation (NASDAQ:OMER) highlighting their lead investigational candidate narsoplimab, which we view as one of the most compelling pipeline candidates in all of the biotech space.
On March 2 after market close, OMER provided some additional updates in conjunction with their 4Q19 results.
First, there is a piece of legislation called the Non-Opioids Prevent Addiction in the Nation (“NOPAIN”) Act which has been introduced